Christian Langer
YOU?
Author Swipe
View article: The Nile and the Yellow River: Comparative Studies between Ancient Egypt and China
The Nile and the Yellow River: Comparative Studies between Ancient Egypt and China Open
This paper explores the evolving landscape of comparative research between ancient Egypt and China, focusing on various aspects such as culture, writing systems, political economy, and motivations behind these comparisons done in China and…
View article: Artificial Targets: a versatile cell-free platform to characterize CAR T cell function in vitro
Artificial Targets: a versatile cell-free platform to characterize CAR T cell function in vitro Open
Cancer immunotherapies using chimeric antigen receptor (CAR) T cells have tremendous potential and proven clinical efficacy against a number of malignancies. Research and development are emerging to deepen the knowledge of CAR T cell effic…
View article: S189: PROTEOGENOMIC LANDSCAPE OF MULTIPLE MYELOMA
S189: PROTEOGENOMIC LANDSCAPE OF MULTIPLE MYELOMA Open
Background: Multiple myeloma is a plasma cell malignancy of the bone marrow. Despite therapeutic advances, it remains incurable and better risk stratification as well as new therapies are therefore highly needed. While genomic alterations …
View article: Molekularpathologie in Gynäkologie und Geburtshilfe
Molekularpathologie in Gynäkologie und Geburtshilfe Open
View article: Long-Term Outcome of a Prospective Randomized Trial Comparing Continuous Lenalidomide/Dexamethasone with Lenalidomide/Dexamethasone Induction, MEL140 with Autologous Blood Stem Cell Transplantation and Single Agent Lenalidomide Maintenance in Patients of Age 60-75 Years with Newly Diagnosed Multiple Myeloma
Long-Term Outcome of a Prospective Randomized Trial Comparing Continuous Lenalidomide/Dexamethasone with Lenalidomide/Dexamethasone Induction, MEL140 with Autologous Blood Stem Cell Transplantation and Single Agent Lenalidomide Maintenance in Patients of Age 60-75 Years with Newly Diagnosed Multiple Myeloma Open
Background: Lenalidomide/dexamethasone has been approved as a standard treatment in multiple myeloma and is applied preferentially in older patients with comorbidities. The addition of daratumumab to this therapy is the best treatment opti…
View article: Multiculturalism and the multicultural in Ancient Egypt
Multiculturalism and the multicultural in Ancient Egypt Open
This paper scrutinizes the characterization of ancient Egyptian society as multicultural and the related use of the concept and terminology of multiculturalism in research and public communications on ancient Egyptian society. An initial o…
View article: Genome-wide meta-analysis of monoclonal gammopathy of undetermined significance (MGUS) identifies risk loci impacting IRF-6
Genome-wide meta-analysis of monoclonal gammopathy of undetermined significance (MGUS) identifies risk loci impacting IRF-6 Open
View article: Full or intensity‐reduced high‐dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma
Full or intensity‐reduced high‐dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma Open
Objective A post hoc subgroup analysis of two phase III trials (NCT00416273, NCT00416208) was carried out to investigate the influence of 100/140 and 200 mg/m² melphalan as well as single/double autologous stem cell transplantation (ASCT) …
View article: Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma
Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma Open
The introduction of new drugs in the past years has substantially improved outcome in multiple myeloma (MM). However, the majority of patients eventually relapse and become resistant to one or multiple drugs. While the genetic landscape of…
View article: Vorbereitungen auf eine pandemische Welle
Vorbereitungen auf eine pandemische Welle Open
View article: O colonialismo informal da Egiptologia: da missão francesa ao Estado de segurança
O colonialismo informal da Egiptologia: da missão francesa ao Estado de segurança Open
Esta contribuição é uma revisão crítica da história colonial da Egiptologia. Ele traça o desenvolvimento do campo desde seus primeiros dias sob o colonialismo europeu e a competição geopolítica intraeuropeia até o advento do controle egípc…
View article: Characterization of rare germline variants in familial multiple myeloma
Characterization of rare germline variants in familial multiple myeloma Open
Multiple myeloma (MM) is a malignancy of plasma cells, characterized by the presence of monoclonal immunoglobulin, known as M protein1. MM is preceded by monoclonal gammopathy of undetermined significance (MGUS) which is also a precursor o…
View article: Forced Labour and Deportations in Ancient Egypt: Recent Trends and Future Possibilities
Forced Labour and Deportations in Ancient Egypt: Recent Trends and Future Possibilities Open
This contribution argues that forced migration and forced labour have been comparatively understudied topics in Egyptology. In this context, it introduces recent research on Egyptian Late Bronze Age deportation policies and paints a compre…
View article: Validation of the revised myeloma comorbidity index and other comorbidity scores in a multicenter German study group multiple myeloma trial
Validation of the revised myeloma comorbidity index and other comorbidity scores in a multicenter German study group multiple myeloma trial Open
View article: c‐MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide‐dexamethasone in myeloma
c‐MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide‐dexamethasone in myeloma Open
Objectives In the TOURMALINE‐MM1 phase 3 trial in relapsed/refractory multiple myeloma, ixazomib‐lenalidomide‐dexamethasone (IRd) showed different magnitudes of progression‐free survival (PFS) benefit vs placebo‐Rd according to number and …
View article: Boundaries, Borders and Frontiers
Boundaries, Borders and Frontiers Open
Boundaries are a complex topic, with different categories being distinguishable depending on the language and with a number of terms often used interchangeably. This discussion paper offers an overview on definitions and introduces differe…
View article: Patterns of Renal Recovery and Toxicity with Novel Agent-Based Induction Triplets in Newly Diagnosed Multiple Myeloma - an Analysis of Two Prospective Studies By the German DSMM Myeloma Study Group
Patterns of Renal Recovery and Toxicity with Novel Agent-Based Induction Triplets in Newly Diagnosed Multiple Myeloma - an Analysis of Two Prospective Studies By the German DSMM Myeloma Study Group Open
Introduction The kidney is an important target organ in plasma cell dyscrasias, subjected to various mechanisms of injury such as tubular obstruction, hypercalcemia, and pre-existing disease. Preservation of kidney function in newly diagno…
View article: Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis
Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis Open
This phase 3 trial compared tandem autologous stem cell transplantation (autoSCT) versus autoSCT followed by reduced-intensity conditioning allogeneic stem cell transplantation (auto/alloSCT) in patients with newly diagnosed multiple myelo…
View article: Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials
Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials Open
Objective A post hoc analysis of two phase III trials was carried out to explore the influence of age and treatment factors on the effect of bortezomib consolidation on progression‐free survival (PFS) post autologous stem cell transplantat…
View article: S825 EVALUATION OF AMG 420, AN ANTI‐BCMA BISPECIFIC T‐CELL ENGAGER (BITE®) IMMUNOTHERAPY, IN R/R MULTIPLE MYELOMA (MM) PATIENTS: UPDATED RESULTS OF A FIRST‐IN‐HUMAN (FIH) PHASE 1 DOSE ESCALATION STUDY
S825 EVALUATION OF AMG 420, AN ANTI‐BCMA BISPECIFIC T‐CELL ENGAGER (BITE®) IMMUNOTHERAPY, IN R/R MULTIPLE MYELOMA (MM) PATIENTS: UPDATED RESULTS OF A FIRST‐IN‐HUMAN (FIH) PHASE 1 DOSE ESCALATION STUDY Open
Background: BCMA, a member of the TNFR family, is expressed on MM and plasma cells (PC). Aims: Objectives of this study included assessing safety and activity of AMG 420/BI 836909, which binds BCMA (B‐Cell Maturation Antigen) on MM cells a…
View article: Allogeneic Transplantation in Multiple Myeloma: Long-Term Follow-Up and Cytogenetic Subgroup Analysis
Allogeneic Transplantation in Multiple Myeloma: Long-Term Follow-Up and Cytogenetic Subgroup Analysis Open
View article: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma.
Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. Open
View article: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma
Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma Open
View article: Enrichment of B cell receptor signaling and epidermal growth factor receptor pathways in monoclonal gammopathy of undetermined significance: a genome-wide genetic interaction study
Enrichment of B cell receptor signaling and epidermal growth factor receptor pathways in monoclonal gammopathy of undetermined significance: a genome-wide genetic interaction study Open
View article: Patient‐reported health‐related quality of life from the phase III TOURMALINE‐MM1 study of ixazomib‐lenalidomide‐dexamethasone versus placebo‐lenalidomide‐dexamethasone in relapsed/refractory multiple myeloma
Patient‐reported health‐related quality of life from the phase III TOURMALINE‐MM1 study of ixazomib‐lenalidomide‐dexamethasone versus placebo‐lenalidomide‐dexamethasone in relapsed/refractory multiple myeloma Open
TOURMALINE‐MM1 is a phase III, randomized, double‐blind, placebo‐controlled study of ixazomib plus lenalidomide and dexamethasone (IRd) versus placebo‐Rd in patients with relapsed/refractory multiple myeloma following 1–3 prior lines of th…
View article: Leptomeningeal Myelomatosis: A Rare but Devastating Manifestation of Multiple Myeloma Diagnosed Using Cytology, Flow Cytometry, and Fluorescent in situ Hybridization
Leptomeningeal Myelomatosis: A Rare but Devastating Manifestation of Multiple Myeloma Diagnosed Using Cytology, Flow Cytometry, and Fluorescent in situ Hybridization Open
Introduction: Involvement of the central nervous system in patients with multiple myeloma is a rare event. We evaluated the diagnostic workup and prognosis of patients with leptomeningeal myelomatosis (LMM). Methods: Between April 2005 and…
View article: Prognostic impact of Ikaros expression in lenalidomide-treated multiple myeloma
Prognostic impact of Ikaros expression in lenalidomide-treated multiple myeloma Open
View article: Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients Open
Key Points IRd was associated with a consistent PFS benefit vs placebo-Rd in RRMM patients with high-risk and standard-risk cytogenetics. The addition of ixazomib to Rd overcomes the poor PFS associated with high-risk cytogenetics in patie…
View article: Phase <scp>II</scp> study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: <scp>DSMM XI</scp> trial
Phase <span>II</span> study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: <span>DSMM XI</span> trial Open
Summary We assessed the safety and efficacy of bortezomib, cyclophosphamide and dexamethasone ( VCD ) induction therapy in previously untreated multiple myeloma patients. A total of 414 patients received three 21‐day cycles of VCD prior to…
View article: Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach
Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach Open